US House Appropriators Have Little Left To Say About Allowing Cannabinoids In Supplements
Appropriation Committee’s report with FDA’s FY2022 funding bill appears to signal that other than getting something done, members have little to say about establishing lawful use of hemp-derived cannabinoids in non-drug products.
You may also be interested in...
One of 72 items in an executive order by the president on promoting competition in the economy notes that 14% of the around 48m US consumers with hearing loss use hearing aids because, on average, they cost more than $5,000 per pair, costs often not covered by health insurance.
Advisory board for CRN-operated Supplement OWL recently reached out to industry for “ultimate reason” of recruiting participation. “Transparency has never been more important and this registry is a demonstration of this industry’s commitment to candor and honesty with our regulators, retailers and consumers,” they say.
Congressional Research Service report says in addition to markets for hemp from fiber, seeds and flowers, “a separate, marketable category exists for the plant’s extracted compounds.” Ingredients from hemp seeds and grains as well as from flowers are alternative protein sources in supplements, foods and beverages and dairy alternatives.